Cerebrolysin
Reviewed
Short answer
Cerebrolysin is not one peptide. It is a pig-brain-derived mixture of small peptides and amino acids. Human trials have studied it, but the largest stroke trial did not prove better recovery. No FDA-approved U.S. product was found.
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Read the study findingsAlso known as Cerebrolysin Ebewe · Cerebrolyzin · FPE 1070 · FPE 1070 (IS) · FPF 1070 (IS) · Renacenz
Legal status Is Cerebrolysin legal? See the status table
Study and product details
What it is
Cerebrolysin is not one peptide. It is a finished product made from a mixture of short peptides produced by breaking down pig-brain proteins in a controlled process. FDA's substance record lists pig brain protein as the source. It calls Cerebrolysin structurally diverse, which means it is a mixture rather than one molecule. The Austrian BASG product information describes an authorized finished product. Because it is a mixture, it has no single amino-acid sequence.
Type of peptide: Pig-brain-derived peptide mixture. This describes what the substance is or how it works. It does not show that it is safe, effective, or approved.
What has been studied?
- Moderate: Useful evidence exists, but important limits remain.
- Limited: Research is too small or incomplete, or does not directly answer this question.
Randomized human studies include a large stroke trial and smaller dementia trials. The largest stroke trial found no significant difference on its main recovery measure.
Cerebrolysin is a mixture, not one defined molecule. Its product information says researchers cannot directly track the whole mixture through the body.
The stroke evidence found a possible increase in serious health problems that did not cause death. Product information also lists important warnings and adverse effects.
High for the named Austrian finished product; low for generic brain hydrolysates, compounded products, or products sold online.
Products with the same ingredient can differ.
The ingredient name does not tell you everything about a product. Check its other ingredients, its form, how it enters the body, and the use and people covered by the research or approval.
None identified in the United States.
- Human research after acute stroke
- Human research in vascular dementia and Alzheimer's disease
Have a lab test report (COA) for a product sold under this name? Check what the report shows in 10 questions
Not sure if a product sold under this name is a prescription, compounded, or research-only vial? Sort it in 5 questions
What studies found
CASTA was the largest randomized stroke trial. It enrolled 1,070 adults with a stroke caused by a blocked blood vessel. Its main recovery measure found no clear difference between Cerebrolysin and placebo. A 2023 Cochrane review covered seven studies and 1,773 people. It included one study of Cortexin, a similar product. The review found no clear drop in deaths. It found a possible rise in serious health problems that did not cause death.
A 2019 Cochrane review covered six vascular-dementia studies with 597 people. Study problems made the evidence very uncertain. Any benefit might be too small to matter. One Alzheimer's study included 192 people, but it did not settle the wider question. FDA has an identity record and an orphan drug designation for Cerebrolysin. Neither means product approval. No FDA-approved U.S. product was found. Online and related brain-peptide products are not proven equal to Cerebrolysin.
Which products do these findings apply to?
Cerebrolysin is a specific finished product made from a pig-brain-derived peptide mixture. An FDA substance record and an Austrian authorization do not make every brain hydrolysate, compounded product, or online product equivalent to Cerebrolysin.
Fact checks
4 statements checked. Read what the results mean.
“Cerebrolysin has been studied in randomized human trials.”
Yes. CASTA and other randomized studies tested the named product in defined groups and settings. The existence of these studies does not prove a benefit for every outcome or product.
- What this answer is based on
- Health results from a study with randomly assigned groups
- Limits of this answer
- The exact Cerebrolysin product, study group, comparison, outcome, and follow-up period in each randomized trial.
Sources for this fact check (3)
“The largest randomized stroke trial proved that Cerebrolysin improves recovery.”
CASTA enrolled 1,070 adults, but its main combined recovery measure showed no significant difference between Cerebrolysin and placebo. A subgroup finding was not the main planned result and does not prove a general recovery benefit.
- What this answer is based on
- Health results from a study with randomly assigned groups
- Limits of this answer
- CASTA: adults with acute ischemic stroke studied for up to 90 days. The result applies to its planned primary measure and study population.
Sources for this fact check (1)
“Cerebrolysin is FDA-approved in the United States.”
No FDA-approved U.S. Cerebrolysin product was identified in the reviewed approval database. An FDA substance record or orphan designation does not mean that FDA approved a product.
- What this answer is based on
- Official record or product label
- Limits of this answer
- United States regulatory status as reviewed August 30, 2026. Austrian authorization is a separate country status.
Sources for this fact check (3)
Show 1 more fact check
“Every pig-brain peptide product is equivalent to Cerebrolysin.”
Cerebrolysin is a specific finished product and mixture. One 2015 sample contained 638 unique peptides. A 2024 study found different contents and activity in related products. A shared pig-brain source does not prove the same identity, contents, quality, or human evidence.
- What this answer is based on
- Official record or product label
- Limits of this answer
- The named Austrian product and the exact product, process, composition, and quality record of any other preparation.
Sources for this fact check (3)
Risks and safety limits
The available evidence does not define the full safety profile of every Cerebrolysin product or related mixture. The 2023 stroke review found a possible increase in serious health problems that did not cause death. This guide does not diagnose, treat, recommend, or provide product-use or sourcing instructions.
Cerebrolysin is not named in the reviewed 2026 WADA Prohibited List. The product is authorized in Austria, so it is not automatically in WADA's S0 group for substances with no government approval. This is not personal clearance. Athletes must check the current list and the rules that apply to their sport.
Reviewed .Check the rules for athletes ↗Read the official rules ↗Terms used in the studies
- peptide
- a short chain of amino acids
- amino acid
- a small building block that makes peptides and proteins
- randomized
- assigned to study groups by chance
- placebo
- an inactive treatment used for comparison
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- molecule
- one specific chemical substance
- outcome
- what the study measured
Read the sources
Show 12 sources
Review history
Initial brief reviewed FDA identity and orphan-designation records, Austrian product information, randomized human trials, composition studies, and the 2026 World Anti-Doping Agency list.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.
Report a factual error